<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.42.1" />
  <meta name="author" content="Burak Kürsad Günhan">

  
  
  
  
    
      
    
  
  <meta name="description" content="Many phase I dose-escalation trials are conducted with flexible dosing regimens, for example starting with a daily dosing and then changing to a weekly dosing. However, standard methods like the Bayesian Logistic Regression Model (BLRM) do not directly allow for more than one dosing regimen to be evaluated, and hence ad-hoc approaches such as simply dose re-scaling are utilized. To overcome this, we propose a new statistical model that uses pharmacokinetic (PK) principles to take into account varying dosing regimens in a model-based approach. We propose to use a latent **pseudo-PK**, which uses the preplanned dosing regimen and the half elimination rate from previous analyses to calculate the exposure measure of the drug. The exposure measure is set proportional to the instantaneous hazard of the time-to-first DLT event process, which gives rise to a time-varying Poisson process. A fully-Bayesian approach is utilized via Stan with weakly informative priors. Our proposed model preserves the advantages of the BLRM, such as interpretable parameters to facilitate defining priors and it allows for the application of the escalation with overdose control principle. The operating characteristics of the proposed procedure were assessed in a Monte Carlo simulation study. The simulation results show that the proposed method has desirable operating characteristics across different true dose-toxicity profiles, especially for combining different dosing regimens scenarios. The proposed method is motivated and illustrated by a real-life example.">

  
  <link rel="alternate" hreflang="en-us" href="/talk/tite_pk_ibc_2018/">

  


  

  
  
  <meta name="theme-color" content="#0095eb">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="Burak Kürsad Günhan">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="Burak Kürsad Günhan">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/talk/tite_pk_ibc_2018/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@burak_guenhan">
  <meta property="twitter:creator" content="@burak_guenhan">
  
  <meta property="og:site_name" content="Burak Kürsad Günhan">
  <meta property="og:url" content="/talk/tite_pk_ibc_2018/">
  <meta property="og:title" content="Guiding Phase I dose-escalation trials with more than one dosing regimen | Burak Kürsad Günhan">
  <meta property="og:description" content="Many phase I dose-escalation trials are conducted with flexible dosing regimens, for example starting with a daily dosing and then changing to a weekly dosing. However, standard methods like the Bayesian Logistic Regression Model (BLRM) do not directly allow for more than one dosing regimen to be evaluated, and hence ad-hoc approaches such as simply dose re-scaling are utilized. To overcome this, we propose a new statistical model that uses pharmacokinetic (PK) principles to take into account varying dosing regimens in a model-based approach. We propose to use a latent **pseudo-PK**, which uses the preplanned dosing regimen and the half elimination rate from previous analyses to calculate the exposure measure of the drug. The exposure measure is set proportional to the instantaneous hazard of the time-to-first DLT event process, which gives rise to a time-varying Poisson process. A fully-Bayesian approach is utilized via Stan with weakly informative priors. Our proposed model preserves the advantages of the BLRM, such as interpretable parameters to facilitate defining priors and it allows for the application of the escalation with overdose control principle. The operating characteristics of the proposed procedure were assessed in a Monte Carlo simulation study. The simulation results show that the proposed method has desirable operating characteristics across different true dose-toxicity profiles, especially for combining different dosing regimens scenarios. The proposed method is motivated and illustrated by a real-life example.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2017-01-01T00:00:00&#43;01:00">
  
  <meta property="article:modified_time" content="2017-01-01T00:00:00&#43;01:00">
  

  
  

  <title>Guiding Phase I dose-escalation trials with more than one dosing regimen | Burak Kürsad Günhan</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">Burak Kürsad Günhan</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#talks">
            
            <span>Talks &amp; Posters</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#teaching">
            
            <span>Teaching</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/Event">

  


  <div class="article-container">

    <div class="pub-title">
      <h1 itemprop="name">Guiding Phase I dose-escalation trials with more than one dosing regimen</h1>
      <span class="pub-authors" itemprop="author">
        
      </span>
      <span class="pull-right">
        
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Guiding%20Phase%20I%20dose-escalation%20trials%20with%20more%20than%20one%20dosing%20regimen&amp;url=%2ftalk%2ftite_pk_ibc_2018%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2ftalk%2ftite_pk_ibc_2018%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2ftalk%2ftite_pk_ibc_2018%2f&amp;title=Guiding%20Phase%20I%20dose-escalation%20trials%20with%20more%20than%20one%20dosing%20regimen"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2ftalk%2ftite_pk_ibc_2018%2f&amp;title=Guiding%20Phase%20I%20dose-escalation%20trials%20with%20more%20than%20one%20dosing%20regimen"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Guiding%20Phase%20I%20dose-escalation%20trials%20with%20more%20than%20one%20dosing%20regimen&amp;body=%2ftalk%2ftite_pk_ibc_2018%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


      </span>
    </div>

    
      <h3>Abstract</h3>
      <p class="pub-abstract" itemprop="text">Many phase I dose-escalation trials are conducted with flexible dosing regimens, for example starting with a daily dosing and then changing to a weekly dosing. However, standard methods like the Bayesian Logistic Regression Model (BLRM) do not directly allow for more than one dosing regimen to be evaluated, and hence ad-hoc approaches such as simply dose re-scaling are utilized. To overcome this, we propose a new statistical model that uses pharmacokinetic (PK) principles to take into account varying dosing regimens in a model-based approach. We propose to use a latent <strong>pseudo-PK</strong>, which uses the preplanned dosing regimen and the half elimination rate from previous analyses to calculate the exposure measure of the drug. The exposure measure is set proportional to the instantaneous hazard of the time-to-first DLT event process, which gives rise to a time-varying Poisson process. A fully-Bayesian approach is utilized via Stan with weakly informative priors. Our proposed model preserves the advantages of the BLRM, such as interpretable parameters to facilitate defining priors and it allows for the application of the escalation with overdose control principle. The operating characteristics of the proposed procedure were assessed in a Monte Carlo simulation study. The simulation results show that the proposed method has desirable operating characteristics across different true dose-toxicity profiles, especially for combining different dosing regimens scenarios. The proposed method is motivated and illustrated by a real-life example.</p>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            
            Jul 10, 2018
            <div class="talk-time">
              
                2:00 PM
                
                  &mdash; 3:00 PM
                
              
            </div>
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Event</div>
          <div class="col-xs-12 col-sm-9">
            <a href="http://2018.biometricconference.org" target="_blank" rel="noopener">
            Poster presentation at IBC conference
            </a>
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Location</div>
          <div class="col-xs-12 col-sm-9">Barcelona, Spain</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    

    <div class="space-below"></div>

    <div class="article-style">
      
    </div>

    


  </div>
</div>



<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2018, Burak Kürsad Günhan &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

